Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era. Issue 3 (26th February 2018)

• Record Type: Journal Article
• Authors: Falade‐Nwulia, O.; Sulkowski, M. S.; Merkow, A.; Latkin, C.; Mehta, S. H.
• Is Part Of: Journal of viral hepatitis. Volume 25:Issue 3(2018)
• Page Start: 220
• Page End: 227
• Publication Date: 2018-02-26
• Subjects: hepatitis C -- men who have sex with men -- people who inject drugs -- reinfection; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12859
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: The availability of effective, simple, well‐tolerated oral direct‐acting antiviral (DAA) hepatitis C regimens has raised optimism for hepatitis C virus (HCV) elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV‐infected men who have sex with men (MSM) however threatens the achievement of this goal from a patient, provider and population perspective. The goal of this review was to synthesize our current understanding of estimated rates and factors associated with HCV reinfection. This review also proposes interventions to aid understanding of and reduce hepatitis C reinfection among PWID and HIV‐infected MSM in the oral direct‐acting antiviral era.